samrotamab vedotin

{
  "id": "MLC-T-ONC-016634",
  "term": "samrotamab vedotin",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) linked, via the protease-cleavable valine-citrulline linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of samrotamab vedotin, the samrotamab moiety targets and binds to LRRC15 expressed on cancer-associated fibroblasts (CAFs) and tumor cells. Upon binding and internalization, MMAE is released after proteolytic cleavage. MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in LRRC15-expressing CAFs and tumor cells. LRRC15, a type I membrane protein and a member of the LRR superfamily, is highly expressed on CAFs in the tumor microenvironment (TME) within some tumor stroma and on tumor cells in certain tumors.",
  "synonyms": [
    "ADC ABBV-085",
    "PR-1498487 PAB-MMAE"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/samrotamab-vedotin/"
}